AbbVie retains Humira market share above 70%: report

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the blockbuster marks its second anniversary of its U.S. biosimilar threat.